Portfolio Companies News
August 17, 2017Altimmune Announces $14.7 Million S...
GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors to sell an aggregate of 15,656 shares of Series B convertible... read more
August 17, 2017MIPS: INTERIM REPORT JANUARY – JU...
APRIL – JUNE Net sales increased by 55% to MSEK 36.6 (23.6) Operating profit rose to MSEK 11.0 (5.6). Adjusted operating profit* increased to MSEK 11.5 (7.4) Operating margin improved to 30.2% (23.7) Adjusted operating margin* increased to 31.5% (31.2) Cash flow from operating activi... read more
August 17, 2017BONESUPPORT - Q2 2017 Interim Repor...
Lund, Sweden, 08.00 CEST, 17 August 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT™ platform today publishes its Interim Report, J... read more
August 16, 2017NEXSTIM PLC HALF-YEARLY REPORT 1 JA...
Company Highlights, January – June 2017 Patient enrolment for Nexstim’s supplementary Phase III Trial in Stroke Rehabilitation (E-FIT) using its NBT® system is progressing well. The data, expected in Q2 2018, will be used for a de novo 510(k) filing with the FDA Nexstim filed a 510(k... read more
August 15, 2017NORDIC NANOVECTOR TO HOST CAPITAL M...
Oslo, Norway, 14 August 2017 Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will host a capital markets day on 22 November 2017. The date has been changed from 27 Septembe... read more
July 14, 2017Q2 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 108 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
22 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.